ClinicalTrials.gg
Not yet recruitingNCT07844629HemEmboUpdated Sep 28, 2026

Comparing Rectal Artery Embolization and Surgery for Treatment of Bleeding Grade 2 and 3 Internal Hemorrhoids

A Phase 2 interventional study of Rectal Artery Embolization and Operative Hemorrhoidectomy in Hemorrhoids Internal, Hemorrhoids Second Degree and Hemorrhoids Third Degree, sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Hemorrhoids with a site in United States — 9 open to participants now, 9 under way, none of them phase 3. Hemorrhoids · United States.

Planned enrollment
9th of 28
102 · median 83
Started
2026
with 4 others
Phase 2
4 of 33
1 open now
Registered
33rd of 33
by date

Among the 33 studies in Hemorrhoids with a site in United States, this one is the 9th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 2, and was the 33rd registered.

Hemorrhoids

240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

Browse Hemorrhoids studies →

Open to participants now

9 of the 33 studies in Hemorrhoids with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Hemorrhoids with a site in United States, or all of them as a file.
02

Study summary

This Phase II study will compare rectal artery embolization with operative hemorrhoidectomy in adults with symptomatic bleeding grade 2 and 3 internal hemorrhoids. Participants will be randomly assigned to receive one of the two treatments. The study will evaluate how each treatment affects quality of life, symptom improvement, bleeding control, recovery time, and treatment-related side effects.

The main question this study is trying to answer is whether rectal artery embolization can provide better short-term quality of life compared with surgical hemorrhoidectomy one month after treatment. The study will also examine whether rectal artery embolization allows patients to return to work and normal activities sooner, reduces hemorrhoid-related bleeding, and has a different rate of treatment-related complications compared with surgery.

A total of approximately 102 adult participants will be enrolled at a single academic medical center. The results of this study may help determine whether rectal artery embolization is an effective and less invasive alternative to surgical hemorrhoidectomy for the treatment of bleeding grade 2 and 3 internal hemorrhoids.

03

Conditions studied

  • Hemorrhoids Internal
  • Hemorrhoids Second Degree
  • Hemorrhoids Third Degree

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged >18 years
  • Goligher grade 2 or 3 internal hemorrhoids not amenable to rubber band ligation in the clinic setting
  • French bleeding score > 5
  • Rectal bleeding greater than 3 months
  • Colonoscopy within three years, negative for colorectal
  • \< 1.5
  • count > 150,000/dL
  • For females of : use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after intervention
  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Current use of anticoagulants and/or DAPT
  • Presence of vascular disease or previous vascular intervention preventing endovascular access to the rectal arteries
  • Prior surgical or endovascular treatment of hemorrhoids
  • Prior endoscopic hemorrhoid artery ligation
  • Pregnancy or lactation
  • Known severe allergic reactions to iodinated contrast not mitigated by standard prophylaxis
  • Bleeding attributable to other anorectal pathology such as anal fissures, anorectal abscess, or fistula
  • Inflammatory bowel disease
  • Inflammatory vasculitis or connective tissue disease
  • Current participation in another clinical trial which may interfere with participation in this study
  • Treatment with bevacizumab within 2 months
  • to surgical management of internal hemorrhoids
  • Primary or secondary involving the abdomen or pelvis which is likely to impact treatment
  • Prior pelvic radiation therapy
  • Prior diagnosis of portal hypertension
  • Major comorbidities expected to impact outcomes or increase patient risk, in the judgement of the enrolling physician
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Rectal Artery Embolization

    Participants will undergo rectal artery embolization for the treatment of symptomatic bleeding Goligher grade 2 and 3 internal hemorrhoids.

    Procedure: Rectal Artery Embolization

  • Active comparator
    Operative Hemorrhoidectomy

    Participants will undergo operative hemorrhoidectomy for the treatment of symptomatic bleeding Goligher grade 2 and 3 internal hemorrhoids.

    Procedure: Operative Hemorrhoidectomy

Interventions

  • ProcedureRectal Artery Embolization

    A minimally invasive procedure in which a doctor uses imaging guidance to place a small catheter into an artery and injects embolization materials to block the blood vessels supplying the hemorrhoids. This reduces blood flow and helps shrink the hemorrhoids.

  • ProcedureOperative Hemorrhoidectomy

    A surgical procedure performed under anesthesia in which the surgeon removes or excises the hemorrhoidal tissue. This is the current standard treatment for severe hemorrhoids.

06

What researchers measure

Primary outcomes

  1. Quality of Life Following Treatment

    Comparison of quality-of-life, as measured by the Short Health Scale for Hemorrhoid Disease, 1 month following superior rectal artery embolization and open surgical hemorrhoidectomy. Scores range from 4 to 28, with lower scores indicating better quality of life and higher scores indicating worse quality of life.

    Time frame: Baseline and 1 month after treatment

Secondary outcomes

  1. Time to Return to Work

    Comparison of time to return to work following superior rectal artery embolization and open surgical hemorrhoidectomy.

    Time frame: From treatment through return to work or normal activities, up to 6 months after treatment

  2. Time to Return to Pre-Intervention Activities

    Comparison of time to return to pre-intervention activities following superior rectal artery embolization and open surgical hemorrhoidectomy as measured by selected elements of the adapted VEINES questionnaire. Scores range from 3 to 12, with higher scores indicating less limitation in daily, social, and leisure activities and therefore better functional recovery. Lower scores indicate greater activity limitation and poorer functional recovery.

    Time frame: From treatment until return to pre-intervention activities, up to 6 months after treatment

  3. Achievement of French Bleeding Score <2

    Comparison of proportion of patients that achieve French Bleeding Scores \< 2 following superior rectal artery embolization and open surgical hemorrhoidectomy for the treatment of bleeding Goligher Grade 2 and 3 internal hemorrhoids. For the French Bleeding Score, total scores range from 0 to 9, with lower scores indicating less bleeding and better clinical outcomes, and higher scores indicating more severe hemorrhoidal bleeding and worse clinical outcomes.

    Time frame: 6 months after treatment

  4. Treatment-Related Adverse Events

    Comparison of adverse events following superior rectal artery embolization and open surgical hemorrhoidectomy for the treatment of bleeding Goligher Grade 2 and 3 internal hemorrhoids.

    Time frame: From treatment through 6 months after treatment

Other outcomes

  1. Correlation of Rectal Arterial Anatomy With Clinical Outcomes

    Evaluate number and size of arteries and correlate with observed outcomes.

    Time frame: Arterial anatomy assessed at the time of procedure; clinical outcomes assessed through 6 months after treatment.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Oct 19, 2026
Primary completionEst.
Oct 19, 2028
CompletionEst.
Oct 19, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07844629
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Oct 19, 2026 (estimated)
Primary completion
Oct 19, 2028 (estimated)
Completion
Oct 19, 2028 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion